However, to the best of our knowledge, our study is the first one investigating PMH therapy separately for ACPA-positive and ACPA-negative RA, and also exploring the risk according to the type of therapy (estrogen only or estrogen plus progestogens). The gene discussed is PRTN3; the disease is rheumatoid arthritis.